Lineage Cell Therapeutics (LCTX) Tax Provisions (2014 - 2023)

Lineage Cell Therapeutics' Tax Provisions history runs 5 years deep, the most recent figure standing at -$1.8 million for Q1 2023.

• On a quarterly basis, Tax Provisions changed N/A year-over-year to -$1.8 million in Q1 2023; TTM through Dec 2023 was -$1.8 million, a 87.62% increase from a year earlier, with the FY2025 full-year figure at -$5.3 million, changed N/A from the prior year.
• Tax Provisions fell to -$1.8 million in Q1 2023 per LCTX's latest filing, from -$41000.0 in the prior quarter.
• Across five years, Tax Provisions topped out at $4.4 million in Q1 2019 and bottomed at -$14.0 million in Q4 2019.
• The 4-year median for Tax Provisions is $229500.0 (2022), against an average of -$1.2 million.
• Biggest YoY gain for Tax Provisions was 149.41% in 2022; the steepest drop was 149.41% in 2022.
• Year by year, Tax Provisions stood at -$14.0 million in 2019, then jumped by 92.78% to -$1.0 million in 2021, then surged by 95.95% to -$41000.0 in 2022, then plunged by 4297.56% to -$1.8 million in 2023.
• Per Business Quant, the three latest LCTX Tax Provisions figures stand at -$1.8 million (Q1 2023), -$41000.0 (Q4 2022), and $500000.0 (Q3 2022).